Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR3824 (proline henagliflozin) in type 2 diabetes mellitus
CTR20202522Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of henagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Hengrui Therapeutics. Started Dec 2020; status: completed.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20202522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202522.